Evidence map›Paper›PMID 36342507›Full record

ArticleApplied microbiology and biotechnology2022

Dual activation profile of monocytes is associated with protection in Mexican patients during SARS-CoV-2 disease.

Gustavo Acosta-Altamirano, Elizabeth Garduño-Javier, Victoria Hernández-Gómez, Jossael Alonso Espinosa, Felipe Vaca-Paniagua, Miriam Rodríguez-Sosa, Imelda Juárez-Avelar, Luis Ignacio Terrazas, Juan Carlos Bravata-Alcántara, Mónica Sierra-Martínez and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Gustavo Acosta-AltamiranoUnidad de Investigación, Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, Estado de México, Mexico.
Elizabeth Garduño-JavierÁrea de Citometría de Flujo, Laboratorio Nacional en Salud: Diagnóstico Molecular Y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Avenida de los Barrios # 1, CP 54090, Tlalnepantla, Estado de México, Mexico.
Victoria Hernández-GómezÁrea de Citometría de Flujo, Laboratorio Nacional en Salud: Diagnóstico Molecular Y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Avenida de los Barrios # 1, CP 54090, Tlalnepantla, Estado de México, Mexico.
Jossael Alonso EspinosaÁrea de Citometría de Flujo, Laboratorio Nacional en Salud: Diagnóstico Molecular Y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Avenida de los Barrios # 1, CP 54090, Tlalnepantla, Estado de México, Mexico.
Felipe Vaca-PaniaguaÁrea de Citometría de Flujo, Laboratorio Nacional en Salud: Diagnóstico Molecular Y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Avenida de los Barrios # 1, CP 54090, Tlalnepantla, Estado de México, Mexico.
Miriam Rodríguez-SosaUnidad de Biomedicina, Facultad de Estudios Superiores Iztacala, UNAM, Tlalnepantla, Estado de México, Mexico.
Imelda Juárez-AvelarUnidad de Biomedicina, Facultad de Estudios Superiores Iztacala, UNAM, Tlalnepantla, Estado de México, Mexico.
Luis Ignacio TerrazasÁrea de Citometría de Flujo, Laboratorio Nacional en Salud: Diagnóstico Molecular Y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Avenida de los Barrios # 1, CP 54090, Tlalnepantla, Estado de México, Mexico.
Juan Carlos Bravata-AlcántaraUnidad de Investigación, Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, Estado de México, Mexico.
Mónica Sierra-MartínezUnidad de Investigación, Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, Estado de México, Mexico.
Jonadab E OlguínÁrea de Citometría de Flujo, Laboratorio Nacional en Salud: Diagnóstico Molecular Y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Avenida de los Barrios # 1, CP 54090, Tlalnepantla, Estado de México, Mexico. je.olguin@iztacala.unam.mx.
Universidad Nacional Autónoma de México · MXUniversidad México Contemporáneo · MXAutonomous University of Tlaxcala · MX

Funding

Fundación Gonzalo Río Arronte S669Programa de Apoyo a Profesores de Carrera (PAPCA) de la FES Iztacala FESI-PAPCA-2021-2022-24Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT UNAM) IA205622Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT UNAM) IA209720
6 · The paper itself

Abstract

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been one of the most catastrophic diseases observed in recent years. It has reported nearly 550 million cases worldwide, with more than 6.35 million deaths. In Mexico, an increased incidence and mortality of this disease were observed, where the immune response has been involved in the magnitude and severity. A critical version of the disease is accompanied by hyperinflammatory responses, with cytokine and defective cellular responses. A detailed understanding of the role of molecules and cells in the immune response during COVID-19 disease may help to generate effective protection mechanisms, improving those we already have. Here we analyzed blood samples obtained from patients at the Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI), Mexico, which were classified according to living guidance for clinical management of COVID-19 by the World Health Organization: asymptomatic, mild, severe, and critical disease. We observed increased interleukin (IL)-6 levels and a T-CD8

Indexed as

COVID-19CytokinesHumansMexicoMonocytesPandemicsSARS-CoV-2CytokinesCOVID-19Dual monocyte activation profileImmune responseSARS-CoV-2T cells

Identifiers

PMID36342507
PMCPMC9640868
OpenAlexW4308475610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.